Jonathan Calkwood

2.2k total citations
15 papers, 415 citations indexed

About

Jonathan Calkwood is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Jonathan Calkwood has authored 15 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 5 papers in Neurology and 4 papers in Oncology. Recurrent topics in Jonathan Calkwood's work include Multiple Sclerosis Research Studies (12 papers), Peripheral Neuropathies and Disorders (5 papers) and Polyomavirus and related diseases (4 papers). Jonathan Calkwood is often cited by papers focused on Multiple Sclerosis Research Studies (12 papers), Peripheral Neuropathies and Disorders (5 papers) and Polyomavirus and related diseases (4 papers). Jonathan Calkwood collaborates with scholars based in United States, Switzerland and Australia. Jonathan Calkwood's co-authors include Cathy Chognot, Daniela Stokmaier, Edward Fox, Jeanette Wendt, Anthony Traboulsee, Derrick Robertson, Kevin Winthrop, Ann Herman, Marianna Manfrini and Amit Bar‐Or and has published in prestigious journals such as Gastroenterology, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Jonathan Calkwood

15 papers receiving 407 citations

Peers

Jonathan Calkwood
Zoé L. E. van Kempen Netherlands
Kristina Kakalacheva Switzerland
Christiane Gasperi Germany
Jiehao Zhou United States
Heather Lang United Kingdom
Rosa Gershtein Israel
Channy Muhn Canada
Paula S. Mobberley‐Schuman United States
Marine Baron France
Sheila Waugh United Kingdom
Zoé L. E. van Kempen Netherlands
Jonathan Calkwood
Citations per year, relative to Jonathan Calkwood Jonathan Calkwood (= 1×) peers Zoé L. E. van Kempen

Countries citing papers authored by Jonathan Calkwood

Since Specialization
Citations

This map shows the geographic impact of Jonathan Calkwood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Calkwood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Calkwood more than expected).

Fields of papers citing papers by Jonathan Calkwood

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Calkwood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Calkwood. The network helps show where Jonathan Calkwood may publish in the future.

Co-authorship network of co-authors of Jonathan Calkwood

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Calkwood. A scholar is included among the top collaborators of Jonathan Calkwood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Calkwood. Jonathan Calkwood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Berkovich, Regina, et al.. (2025). Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series. Frontiers in Immunology. 16. 1527102–1527102. 1 indexed citations
2.
Armuzzi, Alessandro, Raymond K. Cross, Gary R. Lichtenstein, et al.. (2022). DOP45 Long-term cardiac safety of ozanimod in phase 3 clinical program of Ulcerative Colitis and relapsing multiple sclerosis. Journal of Crohn s and Colitis. 16(Supplement_1). i094–i095. 9 indexed citations
3.
Long, Millie D., Gary R. Lichtenstein, Jonathan Calkwood, et al.. (2022). 15: LONG-TERM CARDIAC SAFETY OF OZANIMOD IN PHASE 3 CLINICAL PROGRAM OF ULCERATIVE COLITIS AND RELAPSING MULTIPLE SCLEROSIS. Gastroenterology. 162(7). S–5. 2 indexed citations
4.
Cross, Raymond K., Jonathan Calkwood, Ashwini Pai, et al.. (2021). P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. The American Journal of Gastroenterology. 116(1). S9–S10. 6 indexed citations
5.
Bar‐Or, Amit, Jonathan Calkwood, Cathy Chognot, et al.. (2020). Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis. Neurology. 95(14). e1999–e2008. 230 indexed citations
6.
Cohan, Stanley, Harold Moses, Jonathan Calkwood, et al.. (2018). Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY). Multiple Sclerosis and Related Disorders. 22. 27–34. 42 indexed citations
7.
8.
9.
10.
11.
Calkwood, Jonathan, Timothy Vollmer, Robert J. Fox, et al.. (2015). Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis. International Journal of MS Care. 18(3). 138–146. 7 indexed citations
12.
13.
Bennett, Jeffrey L., Molly Nickerson, Fiona Costello, et al.. (2014). Re-evaluating the treatment of acute optic neuritis. Journal of Neurology Neurosurgery & Psychiatry. 86(7). 799–808. 26 indexed citations
14.
Wray, Sibyl, Robert W. Armstrong, Craig Herrman, et al.. (2011). Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opinion on Drug Delivery. 8(12). 1543–1553. 17 indexed citations
15.
Calkwood, Jonathan, et al.. (1998). Peril to the nerve : glaucoma and clinical neuro-ophthalmology : proceedings of the 45th Annual Symposium of the New Orleans Academy of Ophthalmology, New Orleans, LA, USA, April 25-28, 1996. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zoé L. E. van Kempen Breakdown of academic impact, for papers by Kristina Kakalacheva Breakdown of academic impact, for papers by Christiane Gasperi Breakdown of academic impact, for papers by Jiehao Zhou Breakdown of academic impact, for papers by Heather Lang Breakdown of academic impact, for papers by Rosa Gershtein Breakdown of academic impact, for papers by Channy Muhn Breakdown of academic impact, for papers by Paula S. Mobberley‐Schuman Breakdown of academic impact, for papers by Marine Baron Breakdown of academic impact, for papers by Sheila Waugh
Rankless by CCL
2026